PRODUCT INFORMATION

Ki16425

Item No. 10012659

CAS Registry No.:	355025-24-0
Formal Name:	3-[[[4-[4-[[[1-(2-chlorophenyl) ethoxy]carbonyl]amino]-3-methyl-5-isoxazoly]phenyl]methyl]thio]-propanoic acid
MF:	$C_{23}H_{23}ClN_2O_5S$
FW:	475.0
Purity:	≥95%
UV/Vis.:	λ_{max}: 276 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ki16425 is supplied as a crystalline solid. A stock solution may be made by dissolving the Ki16425 in an organic solvent purged with an inert gas. Ki16425 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of Ki16425 in these solvents is approximately 10 mg/ml.

Ki16425 is sparingly soluble in aqueous buffers. Ki16425 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ki16425 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Lysophosphatidic acid (LPA) is a bioactive lipid mediator that signals through five distinct G protein-coupled receptors (LPA_{1-5}).[1] Ki16425 is a LPA receptor antagonist with selectivity for LPA_1 and LPA_3. It exhibits K_i values of 0.34, 6.5, and 0.93 µM for the human LPA_1, LPA_2, and LPA_3 receptors, respectively, as determined by measuring inositol phosphate production in RH7777-transfected cells.[2] Ki1642, at 10 µM, significantly blocks the response of a variety of cancer cell lines to LPA-induced cell migration.[3]

References

1. Choi, J.W., Lee, C.-W., and Chun, J. Biological roles of lysophospholipid receptors revealed by genetic null mice: An update. *Biochim. Biophys. Acta* **1781(9)**, 531-539 (2008)
2. Ohta, H., Sato, K., Murata, N., *et al.* Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. *Mol. Pharmacol.* **64(4)**, 994-1005 (2003).
3. Yamada, T., Sato, K., Komachi, M., *et al.* Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA. *J. Biol. Chem.* **279(8)**, 6595-6605 (2004).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM